Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in Burkina Faso to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The market for these drugs has been growing steadily in the country due to various factors.
Customer preferences: Burkina Faso has a high prevalence of respiratory diseases, particularly asthma, which has contributed to the increasing demand for bronchodilator drugs. Patients prefer these drugs as they provide quick relief from symptoms such as shortness of breath and wheezing.
Trends in the market: The market for bronchodilator drugs in Burkina Faso has been growing due to the increasing prevalence of respiratory diseases. The demand for these drugs is expected to continue to rise in the future as the population grows and ages. Additionally, the government has been taking steps to improve access to healthcare, which has led to an increase in the number of patients seeking treatment for respiratory diseases.
Local special circumstances: Burkina Faso is a low-income country with a limited healthcare budget. This has led to challenges in providing access to healthcare for all citizens, particularly those in rural areas. However, the government has been working to improve healthcare infrastructure and increase access to essential medicines, including bronchodilator drugs.
Underlying macroeconomic factors: Burkina Faso has a growing economy, but it remains one of the poorest countries in the world. The healthcare sector is underfunded and faces challenges in providing access to essential medicines. However, the government has been working to improve healthcare infrastructure and increase access to essential medicines, including bronchodilator drugs. The pharmaceutical industry in the country is relatively small, but it has been growing in recent years due to increasing demand for medicines.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
